[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-001", "question": "A 63-year-old man with ischemic cardiomyopathy (LVEF 20%) and NYHA class III symptoms despite guideline-directed therapy presents with increasing fatigue and abdominal swelling. BP is 88/54 mm Hg, HR 78/min, JVP 15 cm with prominent v waves, and there is a holosystolic murmur at the left lower sternal border that increases with inspiration. Echo shows severe functional tricuspid regurgitation with right atrial and RV dilation, TAPSE 1.0 cm, RV fractional area change 25%, PASP 42 mm Hg, and no significant left-sided valvular disease. Coronary anatomy is unchanged from prior and not revascularizable. He is in sinus rhythm and not a heart transplant candidate. After optimization of diuretics, he remains symptomatic. Which management strategy is most appropriate to improve outcomes?", "options": ["Surgical tricuspid valve replacement with bioprosthesis", "Catheter-based edge-to-edge tricuspid valve repair", "Isolated LV assist device implantation", "Upgrade to CRT-D with AV node ablation", "Intensification of neurohormonal blockade with sacubitril/valsartan uptitration"], "answer": "B", "answer_index": 1, "explanation": "In advanced HFrEF with severe secondary TR, RV dysfunction, and prohibitive surgical risk, transcatheter edge-to-edge tricuspid repair is preferred and has evidence for symptomatic and functional improvement versus medical therapy alone. Surgical replacement carries high perioperative mortality with poor RV reserve; isolated LVAD can worsen RV failure; CRT-D and further neurohormonal titration are unlikely to meaningfully reverse severe functional TR at this stage.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with end-stage heart failure characterized by severe left ventricular dysfunction (LVEF 20%), severe right ventricular dysfunction (TAPSE 1.0 cm, RV FAC 25%), and severe functional tricuspid regurgitation (TR). He is symptomatic (NYHA III, ascites, edema) and hypotensive (BP 88/54 mm Hg). He is not a candidate for revascularization or heart transplantation.\n\nWe must evaluate the options for \"most appropriate\" management:\n\nA. Surgical tricuspid valve replacement: The patient has extremely high operative risk due to severe biventricular dysfunction and previous ischemic heart disease. Mortality for isolated tricuspid valve surgery is already high and would be prohibitive in this patient, especially given the severe RV dysfunction (TAPSE 10 mm).\n\nB. Catheter-based edge-to-edge tricuspid valve repair (TEER): This patient has severe symptomatic functional TR. Recent pivotal trials (e.g., TRILUMINATE) and guidelines support the use of transcatheter repair (like TriClip) in patients with severe TR who are at high risk for surgery to improve quality of life. While the major trials often excluded patients with *severe* RV dysfunction (e.g., TAPSE < 12-15 mm) and severe LV dysfunction (LVEF < 20%), real-world registries and compassionate use suggest this is often the only structural option left for such patients. Compared to the swift mortality risk of surgery or the high failure risk of an LVAD, TEER is the most appropriate *interventional* strategy to attempt to reduce venous congestion and improve symptoms.\n\nC. Isolated LV assist device (LVAD) implantation: Implantation of an *isolated* LVAD in the setting of severe RV failure (indicated by TAPSE 1.0 cm, clinical signs of right heart failure) is a major predictor of poor outcomes and acute right heart failure post-implantation. These patients typically require biventricular support, and an isolated LVAD would likely be fatal.\n\nD. Upgrade to CRT-D with AV node ablation: Cardiac Resynchronization Therapy (CRT) is indicated for patients with LVEF < 35% and wide QRS (usually LBBB). However, the option includes \"AV node ablation.\" In a patient in sinus rhythm (HR 78/min), AV node ablation is not indicated and would render the patient pacemaker-dependent unnecessarily. AV node ablation is typically reserved for patients with atrial fibrillation and rapid ventricular rates refractory to medication to ensure biventricular capture.\n\nE. Intensification of neurohormonal blockade with sacubitril/valsartan: The patient is hypotensive (BP 88/54 mm Hg). Initiation or uptitration of vasodilators like sacubitril/valsartan is contraindicated as it would likely precipitate cardiogenic shock and renal failure.\n\nTherefore, Transcatheter edge-to-edge repair is the best remaining option among the choices to manage the severe TR and symptoms in this high-risk patient.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-002", "question": "A 41-year-old woman presents with progressive exertional dyspnea and chest tightness. She has no smoking history, takes combined oral contraceptives, and has a brother who died suddenly at 32. Exam shows a loud P2 and a systolic murmur that increases with inspiration. ECG shows right axis deviation and incomplete RBBB. Transthoracic echo reveals severe pulmonary hypertension with estimated PASP 80 mm Hg, normal LV, and RV hypertrophy with preserved function. V/Q scan is normal. Right-heart cath shows: RA 6 mm Hg, RV 90/6 mm Hg, PA 88/32 mm Hg (mean 52), PCWP 9 mm Hg, CI 2.1 L/min/m², PVR 10 Wood units. Acute vasoreactivity testing with inhaled nitric oxide reduces mPAP to 42 mm Hg with unchanged CI and PVR 8 Wood units. Genetic testing is pending. What is the most appropriate initial long-term therapy?", "options": ["High-dose amlodipine monotherapy", "Combination therapy with ambrisentan and tadalafil", "Intravenous epoprostenol monotherapy", "Riociguat monotherapy", "Warfarin with target INR 3.0-4.0"], "answer": "B", "answer_index": 1, "explanation": "She has idiopathic or heritable PAH (group 1) with high-risk features and a negative acute vasoreactivity test (insufficient mPAP reduction and no CI improvement), so calcium channel blocker therapy is contraindicated. Current guidelines favor initial oral combination therapy with an endothelin receptor antagonist and a PDE5 inhibitor (e.g., ambrisentan+tadalafil) for WHO FC II-III with preserved RV function; IV epoprostenol is reserved for higher-risk or rapidly progressive disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with symptoms and signs consistent with pulmonary arterial hypertension (PAH). The diagnosis is supported by the physical exam (loud P2, TR murmur), ECG (RV strain), and right heart catheterization (mPAP > 20 mm Hg, PCWP $\\le$ 15 mm Hg, PVR $\\ge$ 3 Wood units). The normal V/Q scan rules out chronic thromboembolic pulmonary hypertension (CTEPH). The family history of sudden death suggests Heritable PAH.\n\nThe key decision point in initial management is the result of acute vasoreactivity testing.\n*   Definition of a positive responder: A reduction in mean PAP of $\\ge$ 10 mm Hg to reach an absolute mean PAP of $\\le$ 40 mm Hg with increased or unchanged cardiac output.\n*   Patient's result: mPAP decreased from 52 mm Hg to 42 mm Hg. While the reduction is 10 mm Hg, the absolute value is 42 mm Hg, which is not $\\le$ 40 mm Hg.\n*   Conclusion: The patient is a non-responder.\n\nTreatment Guidelines (e.g., ESC/ERS):\n1.  High-dose Calcium Channel Blockers (Option A): Indicated *only* for patients who are vasoreactivity responders. Since this patient is a non-responder, CCBs are contraindicated due to the risk of severe hypotension and clinical deterioration.\n2.  Risk Stratification: The patient has a low-to-intermediate risk profile (RA pressure < 8 mm Hg, preserved RV function, CI 2.1 L/min/m²). She does not exhibit high-risk features such as syncope, overt right heart failure, or a cardiac index < 2.0 L/min/m².\n3.  Initial Therapy:\n    *   Low/Intermediate Risk: Current guidelines strongly recommend initial oral combination therapy targeting two different pathways (e.g., an endothelin receptor antagonist [ERA] and a PDE-5 inhibitor). The AMBITION trial demonstrated that initial combination therapy with Ambrisentan and Tadalafil significantly reduced the risk of clinical failure compared to monotherapy.\n    *   High Risk: Initial combination therapy including a parenteral prostacyclin (e.g., IV epoprostenol) is recommended. This does not apply here.\n    *   Monotherapy (Option D): Generally reserved for patients with very low risk, advanced age, or specific contraindications to combination therapy.\n    *   Anticoagulation (Option E): Warfarin may be considered in IPAH/HPAH, but recommendation strength has decreased in recent guidelines and it is not the primary therapy to treat the pulmonary vasculature.\n    *   IV Epoprostenol (Option C): Reserved for high-risk patients.\n\nTherefore, the most appropriate initial long-term therapy for this non-vasoreactive patient with intermediate-risk PAH is initial combination therapy.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-003", "question": "A 27-year-old man presents with a first generalized tonic-clonic seizure. MRI brain with and without contrast is normal. EEG shows rare generalized spike-and-wave discharges at 3-4 Hz with a photoparoxysmal response. Over the next month he has two more generalized tonic-clonic seizures, each preceded by brief myoclonic jerks on awakening. He drinks socially and works as a software engineer. He and his partner plan to conceive in the next year, and he wants to avoid cognitive side effects. Which antiepileptic monotherapy is most appropriate?", "options": ["Valproate", "Levetiracetam", "Carbamazepine", "Lamotrigine", "Topiramate"], "answer": "B", "answer_index": 1, "explanation": "This is juvenile myoclonic epilepsy with generalized tonic-clonic and myoclonic seizures plus characteristic EEG. While valproate is highly effective, its teratogenicity, metabolic effects, and cognitive risks make it less desirable in a young adult planning pregnancy with a partner and with concerns about adverse effects. Levetiracetam is effective for generalized epilepsies, has a favorable cognitive profile, and minimal drug interactions; carbamazepine can worsen generalized seizures, and lamotrigine/topiramate are less predictably effective for myoclonus.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The clinical presentation is characteristic of Juvenile Myoclonic Epilepsy (JME). The key features include:\n1.  Patient demographics: Onset in adolescence or young adulthood (27-year-old).\n2.  Seizure types: Generalized tonic-clonic seizures (GTCS) and myoclonic jerks, particularly on awakening.\n3.  Triggers: Sleep deprivation and alcohol use are classic triggers.\n4.  EEG findings: Generalized spike-and-wave discharges (typically 4-6 Hz, but 3-4 Hz is consistent with idiopathic generalized epilepsy) and a photoparoxysmal response.\n5.  Normal MRI: Consistent with idiopathic generalized epilepsy.\n\nEvaluation of Antiepileptic Drugs (AEDs):\n\n*   A. Valproate: This is the first-line treatment and gold standard for JME due to its superior efficacy in controlling all seizure types associated with the syndrome (myoclonic, absence, and GTCS). While it has significant teratogenic risks, making it problematic for women of childbearing age, the patient is male. For men, valproate is generally the most appropriate choice due to its high efficacy, especially given the patient has had frequent seizures (three GTCS) recently. While recent scrutiny exists regarding paternal use, standard guidelines still prioritize valproate for men with JME. Regarding cognitive side effects, while valproate can cause tremor or mild slowing, it is not the AED most strongly associated with cognitive dysfunction in this list.\n    \n*   B. Levetiracetam: This is a broad-spectrum AED and a reasonable alternative. However, comparison studies (e.g., SANAD II) have shown valproate to be superior in efficacy for generalized epilepsies. While Levetiracetam has a favorable cognitive profile, it is associated with behavioral side effects (irritability, mood changes). Given the high seizure burden, the most effective agent (Valproate) is preferred.\n    \n*   C. Carbamazepine: This is a sodium channel blocker effective for focal seizures. However, it is contraindicated in JME and other idiopathic generalized epilepsies because it can exacerbate myoclonic and absence seizures.\n    \n*   D. Lamotrigine: While this drug has a favorable cognitive profile (good for a software engineer), it requires a very slow titration (weeks to months) to avoid rash (Stevens-Johnson Syndrome), which is not ideal for a patient with frequent recent seizures. Furthermore, Lamotrigine can sometimes worsen myoclonus in patients with JME.\n    \n*   E. Topiramate: This broad-spectrum AED is effective for JME but is well-known for significant cognitive side effects, often referred to as \"Dopamax\" (e.g., word-finding difficulties, psychomotor slowing, mental dulling). The patient specifically requested to avoid cognitive side effects, making this an inappropriate choice.\n\nConclusion:\nThe \"cognitive side effects\" constraint specifically helps rule out Topiramate. The diagnosis of JME rules out Carbamazepine. The need for rapid control and coverage of myoclonus makes Valproate superior to Lamotrigine. Being male allows the use of Valproate over Levetiracetam, prioritizing the drug with the highest efficacy (Valproate). Therefore, Valproate is the single best answer.\n\nThe answer is (A)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-004", "question": "A 55-year-old woman with a 10-year history of poorly controlled type 2 diabetes presents with episodic confusion, sweating, and palpitations occurring mostly late afternoon. Capillary glucose during an event is 38 mg/dL, resolving with IV dextrose. She takes metformin and basal insulin at night; CGM shows multiple daytime hypoglycemic episodes despite reduction in insulin dose. She denies sulfonylurea use or alcohol. Fasting lab evaluation during supervised 48-hour fast is terminated at plasma glucose 42 mg/dL: insulin 6 μU/mL (normal 2-10), C-peptide 0.1 ng/mL (low), beta-hydroxybutyrate undetectable, and sulfonylurea/meglitinide screen negative. CT of the pancreas is normal. What is the most likely diagnosis?", "options": ["Factitious hypoglycemia from exogenous insulin analog use", "Insulinoma with intermittent secretion", "Non-islet cell tumor hypoglycemia due to IGF-2 secretion", "Autoimmune insulin receptor activating antibody syndrome", "Post-bariatric surgery hyperinsulinemic hypoglycemia"], "answer": "A", "answer_index": 0, "explanation": "Low C-peptide with inappropriately normal insulin at hypoglycemia and absent ketones indicates exogenous insulin, which suppresses endogenous insulin/C-peptide and ketogenesis. Standard insulin immunoassays may underdetect some analogs, yielding low-normal levels; nonetheless, the mismatch of insulin, C-peptide, and ketones supports factitious insulin use rather than insulinoma or IGF-2-mediated hypoglycemia (which would show low insulin/C-peptide but also low ketones via IGF-2 effects).", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This patient presents with Whipple's triad and severe hypoglycemia. The supervised 48-hour fast is the gold standard for evaluation. The key to the diagnosis lies in interpreting the laboratory values obtained at the time of hypoglycemia (plasma glucose 42 mg/dL).\n\n1.  Insulin Level: The patient's insulin level is 6 μU/mL. While the reference range provided (2-10 μU/mL) represents normal fasting levels for a euglycemic patient, physiological insulin secretion should be suppressed (typically < 3 μU/mL) when blood glucose is < 55 mg/dL. An insulin level of 6 μU/mL in the setting of hypoglycemia indicates an excess of insulin (hyperinsulinism) relative to the glucose level.\n2.  C-Peptide Level: C-peptide is secreted in a 1:1 molar ratio with endogenous insulin. The patient's C-peptide is 0.1 ng/mL, which is markedly low/suppressed (normal suppression cutoff is typically < 0.2 nmol/L or < 0.6 ng/mL). A low C-peptide level indicates that beta-cell secretion of insulin is suppressed.\n3.  Synthesis: The combination of detectable/inappropriately normal insulin and suppressed C-peptide is pathognomonic for exogenous insulin administration. The exogenous insulin causes the hypoglycemia and suppresses endogenous beta-cell function (low C-peptide).\n4.  Other Tests:\n    *   Beta-hydroxybutyrate: Undetectable. This confirms a state of insulin excess (insulin inhibits ketogenesis).\n    *   Sulfonylurea screen: Negative. This rules out factitious hypoglycemia due to secretagogues (which would also show high C-peptide).\n    *   CT Pancreas: Normal. This makes insulinoma less likely, but the labs already ruled it out.\n\nAnalysis of Options:\n*   A. Factitious hypoglycemia from exogenous insulin analog use: Matches the profile (High/Normal Insulin, Low C-peptide). The patient has access to basal insulin. Despite reporting dose reductions, the biochemistry proves exogenous insulin is the cause.\n*   B. Insulinoma: Would present with high/inappropriately normal C-peptide because the insulin is endogenous.\n*   C. Non-islet cell tumor hypoglycemia (NICTH): Caused by IGF-2. Insulin levels would be suppressed (usually < 3 μU/mL) due to feedback inhibition.\n*   D. Autoimmune insulin receptor activating antibody syndrome: Antibodies activate the receptor, causing hypoglycemia. Endogenous insulin secretion acts correctly and shuts down. Thus, measured insulin levels would be suppressed (low), and C-peptide would be low.\n*   E. Post-bariatric surgery hyperinsulinemic hypoglycemia: Often due to nesidioblastosis/beta-cell hypertrophy. The insulin is endogenous, so C-peptide would be high.\n\nThe only diagnosis consistent with unsuppressed insulin and suppressed C-peptide is exogenous insulin use.\n\nThe answer is (A)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-005", "question": "A 49-year-old man with poorly controlled hypertension and obesity presents with sudden severe dyspnea and pleuritic chest pain. He is tachypneic, diaphoretic, BP 82/54 mm Hg, HR 128/min, SpO2 86% on non-rebreather. JVP is 12 cm, lungs are clear. Bedside echo shows a dilated RV with McConnell sign and septal flattening; there is no pericardial effusion. CTA confirms a massive saddle pulmonary embolism with bilateral lobar clot burden. While preparing for systemic thrombolysis, he becomes pulseless with PEA. After 10 minutes of ACLS with ongoing CPR and no ROSC, what is the most appropriate next step?", "options": ["Administer full-dose systemic alteplase as a bolus during CPR", "Initiate venoarterial extracorporeal membrane oxygenation (VA-ECMO) followed by catheter-directed thrombectomy", "Administer half-dose systemic alteplase and continue CPR for at least 30 minutes", "Terminate resuscitation efforts due to poor prognosis", "Perform emergency surgical pulmonary embolectomy without ECMO"], "answer": "B", "answer_index": 1, "explanation": "In massive PE with refractory cardiac arrest and no ROSC after high-quality ACLS, VA-ECMO can provide immediate circulatory support and oxygenation, serving as a bridge to definitive reperfusion (catheter-directed or surgical embolectomy). Evidence and expert consensus increasingly support ECMO plus mechanical thrombectomy over late systemic lysis in this setting; halving the alteplase dose or surgical embolectomy without circulatory support are less effective and more dangerous during ongoing arrest.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This patient presents with signs and symptoms of a massive pulmonary embolism (PE) leading to cardiac arrest (PEA). The key features are the history (obesity, hypertension), exam (clear lungs, high JVP), and bedside echo findings (dilated RV, McConnell sign, septal flattening), confirmed by CTA.\n\n1.  Identification of the Clinical Problem: The patient is in cardiac arrest due to an obstructive cause (massive PE). Standard ACLS (CPR, epinephrine) does not treat the underlying mechanical obstruction. Specific therapy to remove or dissolve the clot is required immediately.\n\n2.  Evaluating the Interventions:\n    *   Systemic Thrombolysis (Option A vs C): In the setting of cardiac arrest due to confirmed PE, systemic thrombolysis is the standard First-line treatment recommended by major guidelines (AHA, ESC, ACCP) unless there are absolute contraindications (which are relative in the setting of cardiac arrest). It is the most rapidly available intervention.\n    *   Dosing (Full vs Half): \n        *   Option A (\"Full-dose... bolus\"): The standard systemic thrombolytic dose for massive PE is alteplase 100 mg. In cardiac arrest, this is often administered as a bolus (e.g., 50 mg to 100 mg IV push) rather than an infusion, to achieve rapid therapeutic levels during low-flow states. \"Full-dose\" distinguishes this from the reduced-dose regimens.\n        *   Option C (\"Half-dose\"): Reduced-dose (or \"safe-dose\") thrombolysis (e.g., 50 mg) is primarily studied and recommended for submassive (intermediate-risk) PE to prevent hemodynamic deterioration while minimizing bleeding risk (e.g., MOPETT trial). It is not the standard of care for cardiac arrest, where the mortality risk is immediate and maximal efficacy is needed. Furthermore, while CPR should be continued after administration (often for 60-90 minutes), the dosing makes this option incorrect.\n    *   VA-ECMO / ECPR (Option B): Venoarterial ECMO is an excellent option for PE cardiac arrest as it restores perfusion and oxygenation immediately (ECPR). However, guidelines typically list it as a consideration (Class IIb) or a rescue therapy if thrombolysis fails or is contraindicated, largely due to logistic availability. Unless the scenario specifies a specialized center with immediate ECPR capability at the bedside preventing the need for lysis, systemic thrombolysis is the most appropriate *immediate* \"next step\" universally recognized by ACLS/board standards. Also, the option implies \"Initiating... followed by thrombectomy,\" which is a prolonged process compared to the immediate bolus of tPA.\n    *   Surgical Embolectomy (Option E): This requires Cardiopulmonary Bypass (CPB). The option specifies \"without ECMO,\" which implies operating without extracorporeal circulation support, which is not feasible/standard for a saddle PE embolectomy, or practically impossible in a coding patient without first establishing bypass/ECMO.\n    *   Termination (Option D): Inappropriate. PE is a reversible cause, and guidelines recommend prolonged resuscitation efforts in this context.\n\nConclusion: The most appropriate, guideline-supported immediate action for a patient in cardiac arrest with confirmed massive PE is the administration of systemic thrombolysis.\n\nThe answer is (A)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-006", "question": "A 38-year-old woman presents with progressive proximal muscle weakness over 6 weeks, difficulty climbing stairs, and new-onset dry cough. Exam shows 4/5 strength in hip flexors and shoulder abductors, Gottron papules over MCP joints, and a faint \"mechanic's hands\" rash. CK is 700 IU/L (mildly elevated). High-resolution CT shows bilateral peripheral ground-glass opacities and traction bronchiectasis in lower lobes. Pulmonary function tests show FVC 60% predicted, DLCO 35% predicted, and an FVC/DLCO ratio >1.6. ANA is positive 1:320 speckled. Which specific autoantibody, if present, would indicate the highest risk of rapidly progressive interstitial lung disease requiring aggressive early immunosuppression?", "options": ["Anti-Jo-1 (histidyl-tRNA synthetase)", "Anti-Mi-2", "Anti-MDA5", "Anti-SRP", "Anti-TIF1-γ"], "answer": "C", "answer_index": 2, "explanation": "Anti-MDA5 dermatomyositis is characteristically associated with rapidly progressive, often fatal ILD, even with only mild myositis or CK elevation, and warrants early aggressive combination immunosuppression. Anti-Jo-1 also associates with ILD but usually more indolent; anti-Mi-2 is linked to classic dermatomyositis with good prognosis; anti-SRP to necrotizing myopathy; anti-TIF1-γ to malignancy-associated dermatomyositis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This patient presents with clinical features of dermatomyositis (proximal weakness, Gottron papules) complicated by interstitial lung disease (ILD). The key to answering this question is identifying the specific clinical phenotype and its associated autoantibody.\n\n1.  Clinical Phenotype:\n    *   Cutaneous signs: Gottron papules are pathognomonic for dermatomyositis. \"Mechanic's hands\" are often seen in antisynthetase syndrome but also in anti-MDA5 positive patients.\n    *   Muscle involvement: The CK is 700 IU/L, which is considered mildly elevated in the context of inflammatory myopathies (where values often exceed thousands). This suggests a hypomyopathic or clinically amyopathic dermatomyositis (CADM) variant.\n    *   Pulmonary involvement: The patient has ground-glass opacities and disproportionately low DLCO, indicating significant ILD.\n\n2.  Autoantibody Profiles:\n    *   Anti-Jo-1 (A): Associated with Antisynthetase Syndrome (myositis, ILD, arthritis, mechanic's hands, Raynaud phenomenon). While ILD is very common (70-90%), it often presents as a chronic, slowly progressive disease (NSIP pattern), although acute exacerbations occur.\n    *   Anti-Mi-2 (B): Associated with classic dermatomyositis. It typically has a favorable prognosis with good response to steroids and a low risk of ILD.\n    *   Anti-MDA5 (C): Associated with Clinically Amyopathic Dermatomyositis (CADM). Patients typically have characteristic skin findings (ulcers, palmar papules) and little to no muscle involvement (hypomyopathic, fitting the mildly elevated CK). Most importantly, Anti-MDA5 is strongly associated with Rapidly Progressive Interstitial Lung Disease (RP-ILD), which carries a high mortality rate and necessitates aggressive early immunosuppression (often triple therapy).\n    *   Anti-SRP (D): Associated with immune-mediated necrotizing myopathy (IMNM). It presents with severe muscle weakness and very high CK levels, but ILD is not a predominant feature.\n    *   Anti-TIF1-γ (E): Associated with cancer-associated dermatomyositis. The primary risk is underlying malignancy, not RP-ILD.\n\nConclusion:\nThe combination of dermatomyositis features, mild muscle enzyme elevation (hypomyopathic), and significant pulmonary findings points to the presence of Anti-MDA5 antibodies. This antibody is the specific marker for the highest risk of developing rapidly progressive ILD.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-007", "question": "A 72-year-old man with long-standing COPD (FEV1 35% predicted), chronic hypercapnia, and recent admission for an acute exacerbation requiring noninvasive ventilation is evaluated 3 weeks after discharge. He continues to have daytime somnolence and morning headaches despite resolution of wheeze and normalization of oxygenation on 2 L/min nasal cannula. ABG on his usual oxygen shows pH 7.37, PaCO2 58 mm Hg, PaO2 70 mm Hg, HCO3- 33 mEq/L. Overnight oximetry reveals sustained hypoventilation with episodic desaturations but no significant obstructive apneas. He is adherent to inhaled therapy and pulmonary rehab. What is the most appropriate next step in chronic management to improve mortality?", "options": ["Increase long-term oxygen therapy to maintain PaO2 >80 mm Hg", "Start nocturnal noninvasive ventilation with targeted normalization of PaCO2", "Add chronic low-dose oral prednisone", "Begin acetazolamide at night to stimulate ventilation", "Switch to high-flow nasal cannula at home during sleep"], "answer": "B", "answer_index": 1, "explanation": "In stable COPD with chronic hypercapnic respiratory failure, particularly after a hypercapnic exacerbation, nocturnal noninvasive ventilation targeting PaCO2 reduction reduces mortality and hospitalizations. Increasing oxygen can worsen hypercapnia; chronic steroids confer harm; acetazolamide has limited long-term data; home high-flow therapy improves comfort but lacks robust mortality benefit compared with NIV in this phenotype.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with severe COPD and persistent hypercapnia (PaCO2 > 53 mm Hg) measured 2-4 weeks after a hospital admission for an acute exacerbation requiring acute noninvasive ventilation (NIV). He is also symptomatic with daytime somnolence and morning headaches, which are classic signs of CO2 retention and nocturnal hypoventilation.\n\nThe appropriate management described is based on the results of major clinical trials such as the HOT-HMV trial (Home Oxygen Therapy-Home Mechanical Ventilation) and the trial by Köhnlein et al.\n\n1.  HOT-HMV Trial (2017): Demonstrated that in patients with persistent hypercapnia 2-4 weeks after an acute exacerbation requiring NIV, the addition of home NIV to home oxygen therapy significantly improved admission-free survival compared to home oxygen alone.\n2.  Köhnlein et al. (2014): Showed that in stable hypercapnic COPD patients, \"high-intensity\" NIV (targeted to normalize PaCO2 or reduce it by at least 20%) significantly reduced 1-year mortality compared to standard care.\n\nThe key to the mortality benefit in these studies was the use of high-intensity NIV targeting a significant reduction or normalization of PaCO2, rather than just alleviating symptoms with low pressures.\n\n*   Option A: Increasing oxygen to a PaO2 >80 mm Hg can worsen hypercapnia via the Haldane effect and V/Q mismatch and does not address the underlying alveolar hypoventilation.\n*   Option C: Chronic systemic steroids are associated with significant adverse effects (myopathy, osteoporosis, diabetes) and are not recommended for maintenance therapy to improve mortality.\n*   Option D: Acetazolamide is a respiratory stimulant but is not the standard of care for this indication and lacks the robust mortality data seen with high-intensity NIV.\n*   Option E: While High-Flow Nasal Cannula (HFNC) shows promise in COPD, the evidence for mortality reduction in persistent post-exacerbation hypercapnia is strongest for NIV.\n\nTherefore, the most appropriate next step is to initiate nocturnal NIV targeting a reduction in PaCO2.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-008", "question": "A 59-year-old man with a history of MI and paroxysmal atrial fibrillation presents with acute-onset right eye visual loss described as a \"curtain\" descending over 10 minutes, now partially improved. Exam reveals a right relative afferent pupillary defect and patchy visual field deficit; neurologic exam is otherwise normal. He takes apixaban 5 mg twice daily, metoprolol, and atorvastatin, and reports strict adherence. BP is 130/72 mm Hg. MRI brain with DWI is normal; MRA head/neck shows no large-vessel occlusion or significant carotid stenosis. Fundoscopic exam shows retinal whitening in the inferior arcade consistent with branch retinal artery occlusion (BRAO). Which management strategy is most appropriate regarding his antithrombotic regimen?", "options": ["Continue apixaban and add aspirin 81 mg daily indefinitely", "Switch apixaban to warfarin with target INR 2.5-3.5", "Continue apixaban at the same dose without change", "Increase apixaban dose to 10 mg twice daily for 1 month, then 5 mg twice daily", "Discontinue anticoagulation and use dual antiplatelet therapy for 90 days"], "answer": "C", "answer_index": 2, "explanation": "BRAO in an anticoagulated AF patient is treated as a small ischemic stroke; however, there is no high-level evidence that switching DOACs, adding chronic antiplatelet therapy, or using higher-dose anticoagulation improves outcomes over continuing appropriate-dose DOAC once adherence and dosing are confirmed. Adding aspirin increases bleeding risk without proven benefit; warfarin or dual antiplatelets are not superior for AF-related events when DOAC therapy is adequate.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient is a 59-year-old man with paroxysmal atrial fibrillation (AF) and a history of myocardial infarction who presents with a branch retinal artery occlusion (BRAO) despite reported adherence to apixaban 5 mg twice daily. This represents a recurrent embolic event (anticoagulation \"failure\") while on a direct oral anticoagulant (DOAC).\n\nThe management of recurrent stroke/embolism while on therapeutic anticoagulation is challenging. Guidelines from the American Heart Association/American Stroke Association (2021) and other bodies suggest the following principles:\n1.  Evaluate for other causes: The patient had an MRI/MRA which ruled out large vessel stenosis or other obvious non-cardioembolic etiologies.\n2.  Assess adherence: The patient reports strict adherence.\n3.  Management options: The guidelines state that the usefulness of switching to a different anticoagulant or adding an antiplatelet agent is uncertain (Class 2b). However, they specifically note that continuing the current DOAC is reasonable, as is switching to a different DOAC or warfarin.\n\nLet's evaluate the options provided:\n*   A. Continue apixaban and add aspirin 81 mg daily indefinitely: The addition of aspirin to oral anticoagulation significantly increases the risk of bleeding without a well-established benefit for preventing recurrent stroke in this context. The AFIRE trial (2019) demonstrated that in patients with AF and stable coronary artery disease (more than 1 year post-event), apixaban monotherapy was non-inferior to combination therapy for efficacy and superior for safety (less bleeding). Therefore, finding a history of MI does not justify adding aspirin here.\n*   B. Switch apixaban to warfarin with target INR 2.5-3.5: While switching to warfarin is a potential strategy, the standard target INR for non-valvular AF is 2.0–3.0. A target of 2.5–3.5 is reserved for mechanical mitral valves and possibly certain high-risk antiphospholipid syndrome cases. High-intensity warfarin carries a significantly higher risk of hemorrhage and is not standard recommendation for AF treatment failure.\n*   C. Continue apixaban at the same dose without change: Given that the other options involve incorrect dosing (D), increased bleeding risk with doubtful benefit (A, B), or inappropriate drug class (E), continuing the current guideline-directed medical therapy is the most appropriate evidence-based response. An isolated breakthrough event does not necessarily imply the drug is ineffective, and \"switching\" has not been proven superior to \"continuing\" in randomized trials.\n*   D. Increase apixaban dose to 10 mg twice daily for 1 month, then 5 mg twice daily: This is the loading dose regimen for acute venous thromboembolism (DVT/PE), not for stroke prevention in AF.\n*   E. Discontinue anticoagulation and use dual antiplatelet therapy for 90 days: Dual antiplatelet therapy is inferior to anticoagulation for stroke prevention in AF and is not indicated here.\n\nTherefore, continuing the current regimen is the most appropriate management strategy among the choices provided.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-009", "question": "A 46-year-old man presents with sudden severe tearing chest pain radiating to the back. BP is 210/110 mm Hg in both arms, HR 112/min. CT angiography shows an acute Stanford type B aortic dissection starting distal to the left subclavian artery and extending to the infrarenal aorta with involvement of the origin of the left renal artery, but no signs of rupture or pericardial effusion. The left kidney is perfused via a narrowed true lumen; creatinine is 1.4 mg/dL (baseline 1.0). There is no limb ischemia, mesenteric ischemia, or refractory pain after initial IV beta-blocker and vasodilator therapy, and BP is controlled to 115/70 mm Hg. Which management strategy is most appropriate now?", "options": ["Immediate thoracic endovascular aortic repair (TEVAR) to prevent late aneurysmal degeneration", "Open surgical repair of the descending thoracic aorta due to renal artery involvement", "Strict medical therapy with anti-impulse control and serial imaging", "Prophylactic left renal artery stenting plus medical therapy", "Fenestration and true lumen expansion with balloon angioplasty"], "answer": "C", "answer_index": 2, "explanation": "Uncomplicated type B aortic dissection without rupture, malperfusion, refractory pain, or uncontrolled hypertension is managed initially with aggressive medical therapy and surveillance. Renal artery involvement without clinical malperfusion or progressive renal dysfunction does not mandate immediate TEVAR or intervention; endovascular repair is reserved for complicated cases or aneurysmal progression on follow-up imaging.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This patient presents with an acute Stanford type B aortic dissection. The key decision point in management is classifying the dissection as \"complicated\" or \"uncomplicated.\"\n\n1.  Assessment of Status:\n    *   Complicated TBAD: Defined by the presence of rupture, malperfusion (visceral, renal, limb), refractory pain, rapid progression/expansion, or uncontrolled hypertension. These patients require urgent intervention (usually TEVAR).\n    *   Uncomplicated TBAD: Patients are hemodynamically stable, without signs of rupture or significant malperfusion. Pain and blood pressure are responsive to medical therapy.\n\n2.  Evaluating this Patient:\n    *   Symptoms: Pain is now controlled (\"no refractory pain\").\n    *   Hemodynamics: Blood pressure is well-controlled (115/70 mm Hg) on medication.\n    *   Organ Perfusion: There is imaging evidence of dissection extending into the left renal artery with a \"narrowed true lumen\" and a mild elevation in creatinine (1.4 mg/dL from baseline 1.0). However, there is no refractory hypertension (a hallmark of significant renal ischemia driving renin release) and no severe renal failure, anuria, or acidosis. There is no limb or mesenteric ischemia.\n    *   Classification: Despite the anatomical involvement of the renal artery and mild creatinine bump, the patient is clinically stable with controlled parameters. This is generally managed as uncomplicated TBAD in the acute phase, with close monitoring.\n\n3.  Management Options:\n    *   A. Immediate TEVAR: While TEVAR is the treatment of choice for *complicated* acute TBAD, its limitations in the acute phase for *uncomplicated* cases include a risk of retrograde type A dissection and stroke. The INSTEAD-XL trial showed improved long-term aorta-specific survival with TEVAR + medical therapy vs. medical therapy alone, but the benefit was in preventing late aneurysmal issues, and the intervention in stable patients is often performed in the subacute phase (2 weeks to 3 months) rather than immediately, to allow the aorta to stabilize. Immediate TEVAR is not the standard of care for a currently stable/uncomplicated patient.\n    *   B. Open surgical repair: Associated with high morbidity/mortality; reserved for cases where endovascular repair is not possible.\n    *   C. Strict medical therapy: This is the guideline-recommended initial management (Class I) for acute uncomplicated type B aortic dissection. It involves checking \"anti-impulse\" (heart rate and contractility control, usually with beta-blockers) and blood pressure control. Serial imaging is crucial to detect expansion or progression to malperfusion.\n    *   D & E: Stenting and fenestration are techniques used for treating manifest malperfusion. As the patient is stable with controlled BP, invasive focal interventions are not indicated \"now.\"\n\nSince the patient is hemodynamically stable, pain-free, and has well-controlled blood pressure without signs of critical organ failure, strict medical management is the most appropriate immediate strategy.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-010", "question": "A 24-year-old man presents to the ED after being found confused and agitated. He reports taking an unknown \"research chemical\" for recreation. Vitals: T 40.1°C, HR 146/min, BP 178/104 mm Hg, RR 28/min, SpO2 96% RA. Exam shows mydriasis, diaphoresis, severe agitation with tremor, hyperreflexia, and inducible clonus, but no muscle rigidity. He is not taking prescription drugs and denies MAOI or SSRI use. Labs: Na 138, K 4.1, creatinine 1.0, CK 200 IU/L, normal LFTs. UDS is positive only for amphetamines. Despite high-dose benzodiazepines he remains agitated and hyperthermic. Which is the most appropriate next pharmacologic intervention?", "options": ["Intravenous dantrolene", "Intravenous cyproheptadine via crushed tablets", "Intravenous nitroprusside for blood pressure control alone", "Intravenous dexmedetomidine infusion", "Intravenous bromocriptine"], "answer": "D", "answer_index": 3, "explanation": "This is severe sympathomimetic (likely synthetic stimulant) toxicity with hyperthermia and agitation; there is hyperreflexia but the overall picture and isolated amphetamine screen favor stimulant rather than true serotonin syndrome. When benzodiazepines are insufficient, dexmedetomidine provides sympatholysis and sedation without worsening hyperthermia or respiratory drive as much as deep barbiturate or propofol sedation. Cyproheptadine and dantrolene target serotonin syndrome and NMS, respectively; bromocriptine is used in NMS and would exacerbate sympathomimetic effects.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "Ideally, the management of serotonin syndrome involves discontinuation of the offending agent, supportive care, and benzodiazepines for agitation and neuromuscular hyperactivity. In severe cases or when benzodiazepines are ineffective (refractory), further sedation and specific antidotes are considered.\n\n1.  Diagnosis: The patient exhibits classic signs of Serotonin Syndrome (mental status changes, autonomic instability, and neuromuscular hyperactivity with clonus and hyperreflexia). The history of \"research chemical\" (likely a cathinone or synthetic amphetamine) and absence of muscle rigidity distinguish this from Neuroleptic Malignant Syndrome (NMS), which typically presents with \"lead-pipe\" rigidity and bradykinesia.\n\n2.  Evaluating the Options:\n    *   A. Intravenous dantrolene: Dantrolene is a muscle relaxant that prevents calcium release from the sarcoplasmic reticulum. It is the gold standard for Malignant Hyperthermia and is used in NMS (where rigidity contributes to hyperthermia). However, in serotonin syndrome, the heat generation is driven by central serotonin toxicity leading to myoclonus and agitation, not the sustained contraction seen in rigidity. The vignette explicitly states \"no muscle rigidity,\" making dantrolene mechanistically inappropriate. Furthermore, most toxicology guidelines do not recommend dantrolene for serotonin syndrome.\n    *   B. Intravenous cyproheptadine via crushed tablets: Cyproheptadine is a potent 5-HT2A antagonist and is the specific antidote for serotonin syndrome. However, it is only available in oral formulation. Administering crushed tablets intravenously is a major medical error that can cause pulmonary emboli (granulomas from talc/binders) and infection. While cyproheptadine is the right *drug*, the *route* described is dangerous and incorrect. (In clinical practice, it would be given orally or via NG/OG tube).\n    *   C. Intravenous nitroprusside: While the patient is hypertensive, the hypertension is secondary to the sympathetic surge and agitation. Using a pure vasodilator like nitroprusside without adequate sympatholysis can cause reflex tachycardia (worsening the HR of 146). The priority is treating the agitation and sympathetic outflow.\n    *   D. Intravenous dexmedetomidine infusion: Dexmedetomidine is a central alpha-2 agonist that provides sedation and sympatholysis without significant respiratory depression. It reduces central sympathetic outflow, thereby treating the agitation, tachycardia, and hypertension associated with serotonin toxicity. It is increasingly utilized as an effective adjunct in refractory serotonin syndrome or sympathomimetic toxicity when benzodiazepines are insufficient.\n    *   E. Intravenous bromocriptine: This is a dopamine agonist used for NMS. It is not indicated for serotonin syndrome and could potentially worsen the condition if the drug has serotonergic properties, though its primary mechanism is distinct. The diagnosis is not NMS.\n\nConclusion: Given the failure of benzodiazepines, the need for safe parenteral sedation/sympatholysis, the contraindication of NMS-specific therapies (Dantrolene/Bromocriptine) due to the absence of rigidity, and the impossibility/danger of IV crushed cyproheptadine, dexmedetomidine is the most appropriate choice listed.\n\nThe answer is (D)"}]